ArticlePain and therapy2026
Efficacy of Neuromodulation Therapy for Neuropathy Symptom Reduction and Functional Improvement.
Article in Pain and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lateral Femoral Cutaneous Nerve Radiofrequency Ablation for the Treatment of Meralgia Paresthetica: A Retrospective Case Series.Advances in therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTargeted neuromodulation therapies are increasingly used for the management of peripheral neuropathy; however, data on symptom and functional outcomes following standardized treatment courses remain limited. This report evaluates the efficacy of NeuroGen Neuromodulation treatments administered at the National Neuropathy Center, focusing on changes in sensory symptoms and functional task performance from the first treatment (T1) to the twelfth treatment (T12) over a mean treatment duration of 36 sessions.
methodsPatients completing a standardized 12-treatment course using the NeuroGen Neuromodulation device were analyzed. Outcomes included patient-reported sensory symptoms (tingling, numbness, and pain) and measures of functional task performance. Changes from baseline (T1) to posttreatment (T12) were assessed to determine treatment effectiveness, response patterns, and areas for clinical optimization.
resultsPatients demonstrated clear and measurable benefits following completion of 12 treatments. The greatest improvements were observed in sensory symptoms, with tingling, numbness, and pain each improving by approximately one point on the severity scale. More than half of patients achieved clinically meaningful relief in these sensory domains. Functional improvement was more modest, with meaningful gains observed in approximately one-quarter to one-third of patients. Nonresponse rates were low, although residual symptoms and functional limitations remained common.
conclusionsThe standard NeuroGen Neuromodulation treatment protocol provides substantial relief of sensory neuropathic symptoms, with consistent benefits across patients. While functional gains were less pronounced, the low nonresponse rate supports overall treatment effectiveness. Persistent symptoms in some patients suggest a potential role for maintenance therapy and adjunctive interventions to optimize long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.